Incannex is developing treatments for chronic conditions using cannabinoids and psychedelics. In August 2023, the company announced that its IND application for IHL-42X had been completed, and the Phase II/III trial in obstructive sleep apnoea may proceed. Interim data from the ongoing Australian Phase II trial of psilocybin in combination with psychotherapy in generalized anxiety disorder have been positive; final data are expected in Q423. Final results for ILH-675A in the Phase I trial were announced in Q223, and the asset is now being assessed in Phase II for the treatment of rheumatoid arthritis; Incannex completed a pre-IND meeting with the FDA in July 2023. Incannex recently announced plans to redomicile to the US and list all shares on Nasdaq. Management anticipates the move will enable greater access to capital markets and enhance access to FDA resources.